Sign in
Not yet taking people in PolandPhase 2

Tests TRIV-573 injections for moderate to severe atopic dermatitis

Tests TRIV-573 injections against placebo in adults with moderate to severe atopic dermatitis.

Key facts

Who runs it
Triveni Bio Inc.
Where
Katowice, Kielce, Lublin, Mikolow, Nowa Sol, Poznan, Szczecin, Warsaw, and Wroclaw, PolandSee the 10 sitesAlso in 1 other country, 7 sites
Registry title
A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis
Status
Not yet recruiting
Phase
Phase 2
People taking part
43 people, planned
Starts
1 Dec 2026
Expected to end
8 Feb 2028
Type of study
Interventional
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe, active atopic dermatitis who will receive TRIV-573 or a placebo by injection under the skin.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Moderate to severe, active, chronic atopic dermatitis with symptoms
Earlier treatment
Cannot currently be receiving a nonbiological investigational product or device. Must avoid certain other medications during the study.

Main reasons for not taking part

  • Severe or uncontrolled medical conditions
  • Known chronic liver disease
  • Currently receiving a nonbiological investigational product or device

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Aged 18 to 75 years, inclusive, with a diagnosis of moderate to severe, active, chronic, and symptomatic atopic dermatitis
  • Body weight ≥40 kg (88.2 pounds) at Screening
  • Willing to follow study instructions and avoid certain other medications during the study
  • No significant recent flares in atopic dermatitis

Who cannot take part

  • Currently receiving a nonbiological investigational product or device
  • Severe or uncontrolled medical conditions
  • Known chronic liver disease

Where in Poland

Also in 1 other country, 7 sites

  • Gyncentrum Sp. z o.o.Katowice, PolandNot yet recruiting
  • Provita Sp z o oKatowice, PolandNot yet recruiting
  • Zdybski Med Sp. z o.o.Kielce, PolandNot yet recruiting
  • Clinical Best Solutions Sp. z o.o., Sp. K.Lublin, PolandNot yet recruiting
  • St-Inspire Sp. z o.o.Mikolow, PolandNot yet recruiting
  • Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.Nowa Sol, PolandNot yet recruiting
  • Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.Poznan, PolandNot yet recruiting
  • Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej KrólickiSzczecin, PolandNot yet recruiting
  • Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandNot yet recruiting
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandNot yet recruiting

About the trial

What the trial wants to find out

To assess the efficacy of TRIV-573 administered by SC injection in participants with moderate to severe atopic dermatitis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis
Plain-language title
Tests TRIV-573 injections for moderate to severe atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 October 2026